Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Intravenous dose" patented technology

System and method for measuring and predicting insulin dosing rates

The method and system for managing a patient's blood glucose level predicts an insulin dosing rate to bring a patient's blood glucose level into a preferred target range within a predetermined time interval. The system includes a processor which actuates a blood glucose computer program to measure and predict the patient's blood glucose level. An input mechanism allows for insertion of a preferred target range of the patient's blood glucose level and further permits input of various patient data parameters. The processor calculates the optimum insulin dosing rate for the patient based upon the type of insulin dosing whether it be intravenous dosing and / or subcutaneous dosing. A display mechanism displays the patient dosing parameters and an alarm mechanism alerts a user when the patient's blood glucose level is outside of the preferred patient blood glucose target range.
Owner:GLUCOTEC

Method for assisting in differential diagnosis and treatment of autistic syndromes

InactiveUS7091182B2EffectivenessContinued effectivenessNervous disorderPeptide/protein ingredientsBiliary secretionVein
A novel relationship between pancreatico-biliary secretion and autistic syndrome is disclosed. This relationship enables a novel therapy for the treatment of the symptoms of autistic syndromes, comprising the administration of a therapeutically effective, preferably intravenous, dose of secretin to an individual with autistic syndrome. The relationship further enables a differential diagnosis for autistic syndrome, comprising an analysis of an individual's blood and / or intestinal tissue for the presence of secretin and comparison of the level of secretin to known norms.
Owner:REPLIGEN CORP

Intravenous administration of tramadol

A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours. In certain preferred embodiments, the dosing regimen comprises 50 mg IV tramadol at Hour 0, followed by 50 mg at Hour 2, 50 mg at hour 4, and 50 mg every 4 hours thereafter (e.g., until the patient no longer requires treatment with tramadol).
Owner:REVOGENEX IRELAND

Methods for the treatment of a traumatic central nervous system injury

Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.
Owner:EMORY UNIVERSITY

Methods for diagnosis and intervention of hepatic disorders

The present disclosure concerns methods of administering and detecting a distinguishable agent in a sample from and assessing the condition of an organ in a subject. In a particular embodiment, the present invention concerns methods of detecting and comparing the cholate shunt, in a subject, preferably in a subject with chronic hepatitis C. In certain embodiments, the methods may comprise obtaining a sample from a subject such as a blood or saliva sample after administering an oral and intravenous dose of a distinguishable agent such as cholate and analyzing the sample clearance of the distinguishable agent from the subject and comparing the clearance levels in order to assess hepatic health. In another embodiment, the methods may comprise analyzing a sample from a subject for the presence of a distinguishable agent such as cholate and applying information obtained from analyzing the presence of the distinguishable agent to determine a treatment for a medical condition of the subject.
Owner:UNIV OF COLORADO THE REGENTS OF

Methods for the treatment of a traumatic central nervous system injury

Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.
Owner:EMORY UNIVERSITY

Intravenous administration of tramadol

A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is disclosed. In certain embodiments, the dose is intravenously administered in a time period from about 10 minutes to about 3 hours, preferably from about 10 minutes to about 30 minutes. In other embodiments, intravenous doses are administered at suitable time intervals over a time period from about 3 hours to 48 hours.
Owner:REVOGENEX IRELAND

Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody

A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequence subcutaneous doses.
Owner:JANSSEN BIOTECH INC

Methods of Converting a Patient's Treatment Regimen from Intravenous Administration of an Opioid to Oral Co-Administration of Morphine and Oxycodone Using a Dosing Algorithm to Provide Analgesia

A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.
Owner:QRXPHARMA

Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia

A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.
Owner:QRXPHARMA

Methods for diagnosis and intervention of hepatic disorders

The present disclosure concerns methods of administering and detecting a distinguishable agent in a sample from and assessing the condition of an organ in a subject. In a particular embodiment, the present invention concerns methods of detecting and comparing the cholate shunt, in a subject, preferably in a subject with chronic hepatitis C. In certain embodiments, the methods may comprise obtaining a sample from a subject such as a blood or saliva sample after administering an oral and intravenous dose of a distinguishable agent such as cholate and analyzing the sample clearance of the distinguishable agent from the subject and comparing the clearance levels in order to assess hepatic health. In another embodiment, the methods may comprise analyzing a sample from a subject for the presence of a distinguishable agent such as cholate and applying information obtained from analyzing the presence of the distinguishable agent to determine a treatment for a medical condition of the subject.
Owner:UNIV OF COLORADO THE REGENTS OF

Methods of Converting a Patient's Treatment Regimen from Intravenous Administration of an Opioid to Oral Co-Administration of Morphine and Oxycodone Using a Dosing Algorithm to Provide Analgesia

A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or determining a net average hourly intravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm to determine the first dose of the immediate release morphine-oxycodone combination.
Owner:QRXPHARMA

Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody

A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
Owner:JANSSEN BIOTECH INC

Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aThl composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and / or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.
Owner:IMMUNOVATIVE THERAPIES

Intravenous administration of tramadol

A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours. In certain preferred embodiments, the dosing regimen comprises 50 mg IV tramadol at Hour 0, followed by 50 mg at Hour 2, 50 mg at hour 4, and 50 mg every 4 hours thereafter (e.g., until the patient no longer requires treatment with tramadol).
Owner:REVOGENEX IRELAND

Intravenous injection dosing room and its automatic control system

The invention discloses a liquor preparing room and an automatic control system thereof. The liquor preparing room comprises a liquor preparing handling room with an entrance and further comprises a main fan, a cross flow fan, a filter component, an air supply pipeline, a first FFU (Fan Filter Unit), a second FFU, an air supply plenum chamber and a laminar flow hood, wherein the negative pressure end of the main fan is connected with the filter component; the positive pressure end of the main fan is communicated with the air supply plenum chamber through the air supply pipeline; the air supply plenum chamber and the laminar flow hood are arranged at the top of the liquor preparing handling room; the laminar flow hood is communicated with the air supply plenum chamber; the cross flow fan and the first FFU are mounted in the air supply plenum chamber; the cross flow fan is placed at the top of the entrance of the liquor preparing handling room and blows air downwards to form an airflow barrier; the air outlet of the first FFU is correspondingly arranged above an operating personnel zone; the second FFU is mounted in the laminar flow hood; and the air outlet of the second FFU is correspondingly arranged above a liquor preparing platform. The liquor preparing room provided by the invention is small in size, low in running cost and investment and long in service cycle.
Owner:SICHUAN CHUANJING CLEAN TECH HLDG

Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone by using a dosing algorithm to provide analgesia

A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release mgrphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents, a one-hour average oral morphine equivalents, or determining a net average hourly inlravenous dose, and (2) orally administering to the patient a first dose of a morphine-oxycodone combination in a 3:2 ratio by weight every four to six hours. Also, a method of treating pain in patients who had been administered opioids intravenously, comprising using a dosing algorithm lo determine the first dose of the immediate release morphine-oxycodone combination.
Owner:QRXPHARMA

Method and device for distributing materials of a needle seat assembly of a double-needle-handle medical venous needle

ActiveCN103241540BRealize automatic feeding processBarriers preventing subsequent assemblyConveyor partsVeinMedical device
The invention provides a separation method and a separation device for needle seat assemblies of a double-needle-handle medical vein needle, and belongs to the technical field of medical equipment. The method and the device solve the technical problems that the needle seat assemblies are low in assembling speed and low in efficiency in the prior art. The separation method comprises the following steps of a, discharge, b, feeding, c, intermittent output, and d, reversing adjustment. The separation device comprises a base, wherein strip-shaped feeding groove bodies used for supporting the needle seat assemblies are fixed on the base; vibrators capable of allowing the feeding groove bodies to generate vibration are arranged between the feeding groove bodies and the base; the needle seat assemblies on the feeding groove bodies can be conveyed forward by the vibration of the feeding groove bodies; strip-shaped pressing strips are fixed on the base, parallel to the feeding groove bodies, and located right above the feeding groove bodies; and gaps capable of allowing the needle seat assemblies to pass through are formed between the pressing strips and the feeding groove bodies. The method and the device have the advantages of high assembling speed, high efficiency and the like.
Owner:MAIDER MEDICAL IND EQUIP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products